Oppenheimer analyst Kevin DeGeeter maintained a Buy rating on DermTech (NASDAQ:DMTK) Inc on Friday, setting a price target of $58, which is approximately 41.46% above the present share price of $41.
DeGeeter expects DermTech Inc to post earnings per share (EPS) of -$0.47 for the second quarter of 2021.
The current consensus among 3 TipRanks analysts is for a Strong Buy rating of shares in DermTech, with an average price target of $69.
The analysts price targets range from a high of $79 to a low of $58.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $2.12 million and a net profit of -$9.46 million. The company's market cap is $1.18 billion.
According to TipRanks.com, Oppenheimer analyst Kevin DeGeeter is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 46.4% and a 50.29% success rate.
DermTech, Inc. engages in the development and sale of products for the diagnosis and treatment of skin diseases. It markets and develops products that facilitate the early detection of skin cancers, assesses inflammatory diseases, and customizes drug treatments. Its products include adhesive skin collection kit, pigmented lesion assay, nevome, and carcinome. The company is headquartered in La Jolla, CA.